Beranda › Kanker Prostat Resisten Kastrasi
Uji klinis Kanker Prostat Resisten Kastrasi yang merekrut di AS
18 studi untuk Kanker Prostat Resisten Kastrasi merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Los Angeles, CA8 studi
- New York City, NY7 studi
- Seattle, WA6 studi
- Houston, TX6 studi
- Boston, MA5 studi
- Pittsburgh, PA4 studi
- Queens, NY4 studi
- Philadelphia, PA4 studi
- Mountain View, CA3 studi
- San Francisco, CA3 studi
- Baltimore, MD3 studi
- Dallas, TX3 studi
- Minneapolis, MN3 studi
- St. Louis, MO3 studi
- Nashville, TN3 studi
- Cincinnati, OH3 studi
- Myrtle Beach, SC3 studi
- Grand Rapids, MI3 studi
- Metairie, LA3 studi
- San Diego, CA3 studi
- Arlington, VA3 studi
Berdasarkan negara bagian
- California11 studi
- Connecticut3 studi
- Florida5 studi
- Illinois3 studi
- Louisiana3 studi
- Maryland3 studi
- Massachusetts5 studi
- Michigan7 studi
- Minnesota4 studi
- Missouri3 studi
- Nebraska3 studi
- New Jersey4 studi
- New York8 studi
- North Carolina4 studi
- Ohio4 studi
- Oregon3 studi
- Pennsylvania5 studi
- South Carolina4 studi
- Tennessee5 studi
- Texas7 studi
- Virginia4 studi
- Washington6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Menerima pesertaFase 3
Usia 18 ke atas · Pria · Diperbarui 25 Sep 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Pria · Diperbarui 24 Sep 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Pria · Diperbarui 10 Sep 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Menerima pesertaFase 1
Usia 18 hingga 100 · Pria · Diperbarui 13 Agu 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Pria · Diperbarui 10 Agu 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Menerima pesertaStudi observasional
Usia 18 hingga 115 · Pria · Diperbarui 16 Jul 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaStudi observasional
Usia 18 hingga 115 · Pria · Diperbarui 16 Jul 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Menerima pesertaFase 1/2
Usia 18 ke atas · Pria · Diperbarui 29 Mei 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Menerima pesertaFase 1/2
Usia 18 ke atas · Pria · Diperbarui 6 Mei 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Pria · Diperbarui 13 Apr 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaFase 1/2
Usia 18 ke atas · Pria · Diperbarui 13 Apr 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Pria · Diperbarui 21 Nov 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Menerima pesertaFase 4
Usia 18 ke atas · Pria · Diperbarui 27 Nov 2024 · NCT06706921Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.